Maintenance outage: This site will be inaccessible from late evening Mar 7th thru Mar 8th. This is for scheduled technology upgrades by our global hosting service that are affecting numerous websites and online journals. Note that our submission site is still accessible during this period and processing of new submissions will not be affected.
Follow this preprint
Impact of Providing Future Cardiovascular Risk Based on Genetic Testing on Low-Density Lipoprotein Cholesterol in Patients with Familial Hypercholesterolemia (GenTLe-FH): A Randomized Wait-list Controlled Open-Label Trial
View ORCID ProfileAkihiro Nomura, Hirofumi Okada, Atsushi Nohara, View ORCID ProfileMasaaki Kawashiri, View ORCID ProfileMasayuki Takamura, View ORCID ProfileHayato Tada
doi: https://doi.org/10.1101/2023.03.26.23287767
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Akihiro Nomura
1Innovative Clinical Research Center, Kanazawa University (iCREK), Kanazawa, Japan
2Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
MD, PhDHirofumi Okada
2Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
MD, PhDAtsushi Nohara
3Department of Clinical Genetics, Ishikawa Prefectural Central Hospital, Kanazawa, Japan
MD, PhDMasaaki Kawashiri
4Department of Internal Medicine, Kaga Medical Center, Kaga, Japan
MD, PhDMasayuki Takamura
2Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
MD, PhDHayato Tada
2Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
MD, PhD
Posted March 27, 2023.
Impact of Providing Future Cardiovascular Risk Based on Genetic Testing on Low-Density Lipoprotein Cholesterol in Patients with Familial Hypercholesterolemia (GenTLe-FH): A Randomized Wait-list Controlled Open-Label Trial
Akihiro Nomura, Hirofumi Okada, Atsushi Nohara, Masaaki Kawashiri, Masayuki Takamura, Hayato Tada
medRxiv 2023.03.26.23287767; doi: https://doi.org/10.1101/2023.03.26.23287767
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
0
Author Videos
Subject Areas
- Addiction Medicine (412)
- Allergy and Immunology (726)
- Anesthesia (214)
- Cardiovascular Medicine (3107)
- Dermatology (263)
- Emergency Medicine (463)
- Epidemiology (13046)
- Forensic Medicine (13)
- Gastroenterology (862)
- Genetic and Genomic Medicine (4866)
- Geriatric Medicine (449)
- Health Economics (751)
- Health Informatics (3068)
- Health Policy (1108)
- Hematology (410)
- HIV/AIDS (962)
- Medical Education (453)
- Medical Ethics (120)
- Nephrology (502)
- Neurology (4631)
- Nursing (247)
- Nutrition (689)
- Oncology (2393)
- Ophthalmology (677)
- Orthopedics (270)
- Otolaryngology (333)
- Pain Medicine (306)
- Palliative Medicine (88)
- Pathology (516)
- Pediatrics (1243)
- Primary Care Research (522)
- Public and Global Health (7201)
- Radiology and Imaging (1606)
- Respiratory Medicine (944)
- Rheumatology (460)
- Sports Medicine (403)
- Surgery (514)
- Toxicology (65)
- Transplantation (222)
- Urology (190)